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ABSTRACT
Background: The number of patients who require treatment with proton
pump inhibitors (PPIs) is increasing in Japan. One of their adverse effects is diarrhea.
Objectives: We investigated the incidence of diarrhea caused by 3 different
PIs: lansoprazole, rabeprazole, and omeprazole.
Methods: Patients using PPIs for 1 month were enrolled. Enrolled patients
ecorded daily stool frequency, stool consistency using the Bristol Stool Scale Form,
nd impaired quality of life caused by diarrhea for 1 month. Their attending
hysicians described the types and dosages, and duration of PPI administration, as
ell as other necessary information.
Results: A total of 255 patients participated. Mean age of the patients was
70.7 years old. During the 1-month observation period, 3.5% of the patients
complained of diarrhea. There was no significant difference for the incidence of
diarrhea among the 3 types of PPIs. Furthermore, no correlations between diarrhea
and length and dosage of PPI administration were found.
Conclusions: The incidence of diarrhea in patients receiving long-term
therapy did not differ among 3 different PPIs. ClinicalTrials.gov identifier: UMIN ID
000005300. (Curr Ther Res Clin Exp. 2012;73:112–120) © 2012 Elsevier HS Jour-
nals, Inc. All rights reserved.
Accepted for publication March 19, 2012. http://dx.doi.org/10.1016/j.curtheres.2012.03.002
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INTRODUCTION
The number of patients who require regular proton pump inhibitor (PPIs) is increas-
ing in Japan, and those with gastroesophageal reflux disease (GERD) or upper
gastrointestinal ulcers often use PPIs to suppress gastric acid secretion. The preva-
lence of GERD is increasing remarkably in Japan, and is reported to be as high as
17.9% of the population.1,2 The prevalence of upper gastrointestinal ulcers caused by
nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin has also been
reported to be increasing.3,4
Although PPIs are generally regarded as safe when used for long periods, several
dverse effects, including osteoporosis and vitamin B12 deficiency, have been reported
with high doses. In addition, diarrhea is known to be 1 such adverse event observed
in long-term PPI users.5
There are 3 types of PPIs generally used in Japan: lansoprazole, rabeprazole, and
meprazole. Lansoprazole has been reported to be associated with a high risk of
eveloping collagenous colitis with chronic watery diarrhea,6,7 although this remains
controversial.8 Although lansoprazole-related collagenous colitis is a rare clinical
condition and generally resolves after cessation of lansoprazole administration, diar-
rhea impairs the quality of life (QOL) of affected patients regardless of the presence
of collagenous colitis.9,10 Therefore, we investigated whether lansoprazole causes
iarrhea more frequently than other PPIs and whether lansoprazole had a greater risk
o cause diarrhea in long-term users.
METHODS
Patients receiving PPIs at outpatient clinics of 7 medical centers and 3 primary care
physicians in the Sanin area of western Japan were prospectively enrolled in this
study. We targeted outpatients who were taking a PPI for 1 month and were 20
ears old. Patients diagnosed with irritable bowel syndrome, taking medication for
onstipation, and taking a PPI on an on-demand basis were excluded. The protocol
f this study was evaluated and approved by the ethical committee of Shimane
niversity School of Medicine, and informed consent was obtained from all enrolled
atients.
Enrolled patients were instructed to keep a daily record concerning occurrences of
iarrhea and loose bowels for 1 month, in which they described the frequency of
efecation, stool form according to the Bristol Stool Scale Form, and diarrhea-related
OL impairment. We categorized QOL impairment as 5 grades: grade 1, not
mbarrassed; grade 2, slightly embarrassed; grade 3, somewhat embarrassed (able to
erform usual daily tasks); grade 4, very embarrassed (unable to perform usual daily
asks); grade 5, embarrassed to the point that it was not possible to endure (often in
he restroom). Their attending physicians described the type and dosage of the
rescribed PPI, duration of administration, underlying disease that required a PPI,
113
Current Therapeutic Researchand coadministered drugs. Diarrhea was defined as the state in which the patient had
soft stools (grade 6 or 7 according to Bristol Stool Scale Form) at least 3 times a day
for 8 days during the 1-month observation period, as well as no hard stools (grade
1 or 2) during that period. Loose bowels were defined as the state in which the patient
had soft stools (grade 6 or 7) 4 times within the 1-month observation period and
no hard stools (grade 1 or 2).
We observed the course of bowel movements in patients diagnosed with diarrhea.
When diarrheal symptoms spontaneously improved, we considered that the diarrhea
was likely not caused by microscopic colitis or other particular bacterial pathogens.
When the symptoms persisted, general antidiarrheal medication was prescribed for a
set period of time. If that was not effective, we performed colonoscopy and patho-
logical examinations to investigate the cause of the chronic diarrhea.
Comparisons among the 3 different PPIs were performed using a 2 test. The
correlation between the frequency of Bristol Stool Scale Form grade 6 or 7 soft stools
and length of PPI administration was examined using regression analysis. The
difference in frequency of Bristol Stool Scale Form grade 6 or 7 soft stools between
low- and high-dose PPI users was examined using a Mann-Whitney U Test. A P value
0.05 was considered statistically significant.
RESULTS
Two hundred seventy-nine patients receiving long-term PPI administration were
enrolled in this study, of whom 264 reported their bowel habits by keeping daily
records for 1 month. From those, we excluded 9 patients because of insufficient
descriptions; thus, a total of 255 patients were analyzed in this study. The mean age
of the enrolled patients was 70.7 years old. Patients with diarrhea and loose bowels
during the study period comprised 3.5% and 7.1%, respectively, of the total cohort.
Of all the patients with diarrhea, 1 patient who took low-dose omeprazole reported
significant QOL impairment (grade 5), whereas 3 (1 taking high-dose omeprazole,
and 2 taking low-dose omeprazole) reported impairment that varied between grades
4 and 5.
All the patients, except 3 who had diarrhea during the 1-month observation
period, were followed and confirmed to recover from the diarrhea spontaneously soon
after the observation period without any specific treatment and with continuous
administration of the same PPIs. Therefore, in these cases, neither colonoscopy nor
stool culture was performed. In 2 of the remaining 3 patients, colonoscopy and
histopathological examination did not show any sign of microscopic colitis. In 1 of
these 2 patients, bacterial culture of stool specimens was done, but did not show the
growth of any specific pathogenetic bacteria. Diarrhea of these cases also spontane-
ously resolved during the continuous PPI administration. The remaining 1 patient
who did not undergo colonoscopy had diarrhea continuously before the start of PPI
administration. The frequency and intensity of the diarrhea did not change after the
start of PPI administration in this case. Thus, all the diarrhea reported in the
observation period was not caused by microscopic colitis or by any specific pathoge-
netic bacterial infection.
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S. Shimura et al.We divided the 255 patients into 3 groups based on the type of PPI administered
lansoprazole, n 75; rabeprazole, n 96; omeprazole, n 84) (Table I). Although
here was a small but significant difference for the duration of PPI treatment among
he 3 groups, there were no significant differences for the other clinical characteristics.
e also compared the numbers of patients with diarrhea and loose bowels during the
-month observation period among the 3 groups. Patients who had diarrhea com-
rised 4.0%, 1.0%, and 6.0% of those in the lansoprazole, rabeprazole, and omepra-
ole groups, respectively (Figure 1), whereas those with loose bowels comprised
.0%, 4.2%, and 10.1%, respectively (Figure 2). The differences for diarrhea and
oose bowels were not significant among the groups, although the rabeprazole-treated
roup tended to have lower values.
When the percentage of days with grade 6 or 7 soft stools (Bristol Stool Scale
orm) during the study period was plotted against the length of PPI administration
nd dose in each patient, there were no correlations found (Figures 3 and 4).
We also retrospectively investigated how many patients in each PPI-treated
roup had a change in type of PPI administered before the study period because
f diarrhea possibly related to the drug. Only 2 of the 255 patients changed the
ype of PPI, 1 of whom changed from rabeprazole to lansoprazole and the other
rom lansoprazole to omeprazole because of diarrhea possibly caused by the PPI.
one of the patients discontinued PPI use because of diarrhea during the study
Table I. Clinical characteristics of patients taking proton pump inhibitors (PPIs).
Lansoprazole Rabeprazole Omeprazole P
o. 75 96 84
osage of PPI (half-dose:
full-dose)
44:31 87:9 33:51 NS
ender (M:F) 40:35 50:46 43:41 NS
ge, y (min, max) 70.87 (31, 92) 70.58 (36, 87) 70.61 (39, 89) NS
eriod of PPI administration,
mo (min, max)
33.09 (1.180) 29.82 (1.132) 22.89 (1.66) 0.03
asal diseases requiring PPI
administration
Reflex esophagitis 58 76 61
Gastroduodenal disease 13 17 20 NS
Others 3 6 5
ther co-administered drugs
Aspirin 8 11 12
NSAIDs 2 5 2 NS
Others 57 72 58
NSAIDs  nonsteroidal anti-inflammatory drugs.eriod.
115
tCurrent Therapeutic ResearchDISCUSSION
We examined and compared the incidence of diarrhea in 255 long-term PPI users in
Japan. The rate of occurrence of diarrhea in all patients was 3.5%. Diarrhea is not a
rare symptom and frequently reported by a variety of patients, regardless of drug
use.11 One study noted that 2.1% of hospital inpatients reported diarrhea during
heir hospital stay, and that 1.5% of the causes of admission was diarrhea.12 Fur-
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Figure 1. Percentage of enrolled patients with diarrhea during the 1-month observation
period in 3 groups treated with different proton pump inhibitors. There were no
statistically significant differences among the lansoprazole, rabeprazole, and
omeprazole groups, although the incidence was slightly lower in the rabeprazole
group.
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Figure 2. Percentage of enrolled patients who had loose bowels during the 1-month
observation period in 3 groups treated with different proton pump inhibitors.
There were no statistically significant differences among the lansoprazole, ra-
beprazole, and omeprazole groups, although the incidence was slightly lower in
the rabeprazole group.
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S. Shimura et al.thermore, the prevalence of diarrhea-predominant irritable bowel syndrome in a clinic
population was reported to be as high as 31%,13 whereas antibiotics were reported to
ause diarrhea in up to 25% of patients in another study.14 In comparison with those
eports, the occurrence of diarrhea in our PPI-administered patients was low, indi-
ating the safety of the drugs. The occurrence rate of diarrhea observed in this study
as similar to that reported by Reilly15 for PPI users, and confirmed the generally
eak correlation between PPI administration and diarrhea.
It was reasonable that patients taking higher doses of a drug for longer periods
hould have a greater chance to experience an adverse effect. Because the diarrhea
bserved in the study patients was neither dosage nor time dependent, the diarrhea
bserved in the patients receiving PPIs might not be a toxic adverse reaction to the
rug.16
We compared the incidence of diarrhea and loose bowels among patients receiving
different kinds of PPIs, and found no significant differences. None of the present
ohort had collagenous colitis. Therefore, our results did not support our speculation
hat lansoprazole caused diarrhea more frequently than other PPIs partly because of
nduction of collagenous colitis. A number of investigators reported that lansoprazole
aused microscopic colitis, including collagenous colitis,17 although contrasting
evidence was also presented.18 Because nearly all reports of PPI-related microscopic
colitis were case series or case–control studies, a prospective randomized study is
necessary to determine whether lansoprazole is associated with a higher risk of
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Figure 3. The percentage of days with Bristol Stool Scale Form grade 6 or 7 soft stools
during the 1-month observation period was plotted against the length of proton
pump inhibitor (PPI) administration for each patient. There was no correlation
between soft stool days and length of PPI administration. Black diamonds,
lansoprazole; black squares, rabeprazole; black triangles, omeprazole.microscopic colitis.
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Current Therapeutic ResearchIn addition to collagenous colitis, PPI administration might cause diarrhea via
everal different mechanisms, including easier colonization of enteropathogenic bac-
eria, inadequate protein digestion in the stomach, and a possible influence on H,
-ATPase in the colonic mucosa. In the absence of gastric acid, several kinds of
acteria, including Clostridium difficile, Salmonella, and Campylobacter species, were
eported to easily colonize in the gut, causing enterocolitis accompanied by diarrhea
r loose bowels.19,20 Therefore, inhibition of gastric acid secretion by PPI adminis-
tration may cause diarrhea. Takahashi et al21 reported the presence of nongastric H,
K-ATPase in the human colon and suggested a role for this pump in regulation of
colonic fluid secretion. Thus, in addition to collagenous colitis, any type of PPI may
cause diarrhea as an adverse effect, although the risk might not be high and not
clinically relevant.
Freston et al22,23 reported a similar incidence of diarrhea between lansoprazole,
omeprazole, and placebo treated groups in clinical studies, and also reported that
most of the diarrhea observed resolved spontaneously while patients continued PPIs.
In addition, a recently reported cohort study, comparing PPI and antireflux surgery
as a long-term treatment of GERD, showed a similar incidence of diarrhea between
the 2 treatment strategies.24 Therefore, PPI-related diarrhea might not be a critical
adverse effect that significantly decreases the therapeutic value of PPI.
This prospective observational study had some possible limitations, including its
open-label design and the small size of the cohort. Chande et al25 reported only 14
cases of lansoprazole-induced microscopic colitis in a PubMed literature review from
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Figure 4. The percentage of days with Bristol Stool Scale Form grade 6 or 7 soft stools
during the 1-month observation period in each patient was plotted separately for
those who received half- and full-dose administration of proton pump inhibitors
(PPIs). There was no dose-dependent increase in days with soft stools. Black
diamonds, lansoprazole; black squares, rabeprazole; black triangles, omeprazole.1980 to August 2006. From the expected incidence of microscopic colitis in patients
118
S. Shimura et al.treated with PPIs, the size of our study was too small to make any conclusions
regarding relative incidence of microscopic colitis with the different PPIs. Future
larger studies are necessary to clarify the risk of diarrhea associated with administra-
tion of different PPIs.
CONCLUSIONS
Our findings indicated that the incidence of diarrhea related to PPI use in Japan was
5%. Furthermore, there was no difference in diarrhea occurrence among the 3
different PPIs examined.
ACKNOWLEDGMENTS
The following physicians supported the enrollment of patients in this study: Kat-
suhisa Sonoyama, Sonoyama Clinic, Izumo; Nobuo Ashizawa, Tamatsukuri Koseinen-
kin Hospital, Matsue; Akira Kawamura, Ono Municipal Hospital, Ono; Koutaro
Shibagaki, Tottori Municipal Hospital, Tottori; Naoto Kitajima, Kasai city hospital,
Kasai; Koichiro Furuta, Masuda Medical Association Hospital, Masuda; Chikara
Kadota, Takatsuki General Hospital, Takatsuki; and Tatsuya Miyake, Hiroshi Tobita,
Norihisa Ishimura, Hideaki Kazumori, Syuichi Satou, Takafumi Yuki, and Yuji
Amano, Shimane University School of Medicine, Izumo.
Drs. Shimura, Furuta, and Kinoshita contributed equally to this work. Drs. Shimura,
Furuta, Adachi, and Kinoshita designed research. Drs. Shimura, Furuta, Hamamoto,
Yoshino, Kushiyama, Fujishiro, Komazawa, Ishihara, Adachi, and Kinoshita performed
research. Drs. Shimura, Furuta, Adachi, and Kinoshita analyzed data and wrote the
manuscript.
CONFLICTS OF INTEREST
Dr. Kinoshita served as a consultant for Eisai Co, Ltd, AstraZeneca Pharmaceuticals,
and Takeda Pharmaceutical Company Ltd. The authors have indicated that they have
no other conflicts of interest regarding the content of this article.
REFERENCES
1. Mishima I, Adachi K, Arima N, et al. Prevalence of endoscopically negative and positive
gastroesophageal reflux disease in the Japanese. Scand J Gastroenterol. 2005;40:1005–1009.
2. Fujishiro H, Adachi K, Kawamura A, et al. Influence of Helicobacter pylori infection on the
prevalence of reflux esophagitis in Japanese patients. J Gastroenterol Hepatol. 2001;16:1217–1221.
3. Ootani H, Iwakiri R, Shimada R, et al. Role of Helicobacter pylori infection and nonsteroidal
anti-inflammatory drug use in bleeding peptic ulcers in Japan. J Gastroenterol. 2006;41:41–46.
4. Shiotani A, Kamada T, Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past,
present, and future. J Gastroenterol. 2008;43:581–588.
5. Thomson ABR, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton
pump inhibitors. World J Gastroenterol. 2010;16:2323–2330.
6. Umeno J, Matsumoto T, Nakamura S, et al. Linear mucosal defect may be characteristic of
lansoprazole-associated collagenous colitis. Gastrointest Endosc. 2008;67:1185–1191.
7. de la Iglesia Fanjul I, de Castro Losa MR, Izquierdo García F. Collagenous colitis. Clinico-
pathological study of 18 cases [in Spanish, Abstract in English]. Revista Clin Espaola. 2007;
207:394–398.
119
11
1
1
1
1
1
1
2
2
2
2
2
2
Current Therapeutic Research8. Keszthelyi D, Jansen SV, Schouten GA, et al. Proton pump inhibitor use is associated with an
increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther. 2010;32:
1124–1128.
9. Hilmer SN, Heap TR, Eckstein RP, et al. Microscopic colitis associated with exposure to
lansoprazole. Med J Aust. 2006;184:185–186.
10. Williams JJ, Beck PL, Andrews CN, et al. Microscopic colitis-common cause of diarrhoea in
older adults. Age Ageing. 2010;39:162–168.
11. Pilotto A, Franceschi M, Vitale D, et al. The prevalence of diarrhea and its association with
drug use in elderly outpatients: a multicenter study. Am J Gastroenterol. 2008;103:2816–2823.
2. Gangarosa RE, Glass RI, Lew JF, Borning JR. Hospitalizations involving gastroenteritis in the
United States, 1985: the special burden of the disease among the elderly. Am J Epidemiol.
1992;135:281–290.
3. Shinozaki M, Fukudo S, Hongo M, et al. High prevalence of irritable bowel syndrome in
medical outpatients in Japan. J Clin Gastroenterol 2008;42:1010–1016.
4. Christoph H, Heinz FH, Guenter JK, Emil CR. Mechanisms and management of antibiotic-
associated diarrhea. Clin Infect Dis. 1998;27:702–710.
5. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm. 1999;
56:11–17.
6. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management.
Lancet. 2000;356:1255–1259.
7. Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported
during treatment with proton pump inhibitors used in general practice in England: cohort
studies. Br J Clin Pharmacol. 2000;50:366–372.
8. Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesoph-
ageal reflux disease. Am J Manag Care. 2000;6:491–505.
9. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk
of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294:2989–2995.
0. García Rodríguez LA, Ruigómez A, Panés J. Use of acid-suppressing drugs and the risk of
bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007;5:1418–1423.
1. Takahashi Y, Sakai H, Kuragari M, et al. Expression of ATP1AL1, a non-gastric proton pump,
in human colorectum. Jpn J Physiol. 2002;52:317–321.
2. Freston JW, Rose PA, Heller CA, et al. Safety profile of lansoprazole: The US Clinical Trial
Experience. Drug Saf. 1999;20:195–205.
3. Freston JW, Hisada M, Peura DA, et al. The clinical safety of long-term lansoprazole for the
maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther. 2009;29:1249–1260.
4. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic Antireflux Surgery vs Esomeprazole
Treatment for Chronic GERD: The LOTUS Randomized Clinical Trial. JAMA. 2011;305:
1969–1977.
5. Chande N, David KD. Microscopic colitis associated with lansoprazole: report of two and a
review of the literature. Scand J Gastroenterol. 2007;42:530–533.
Address correspondence to: Kenji Furuta MD, PhD, Department of
Gastroenterology and Hepatology, Shimane University School of Medicine, Enya-cho
89–1, Izumo-shi, Shimane 693–8501, Japan. E-mail: kfuruta@med.shimane-u.ac.jp
120
